English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

This real-world study assessed the breast cancer susceptibility gene 1 or 2 mutation (BRCA1/2mut) status on treatment patterns, safety, and patient-reported outcomes (PROs) in women with human epidermal growth factor receptor 2–negative (HER2-) advanced breast cancer (ABC) in the United States, United Kingdom, and EU4 countries.Methods: Oncologists abstracted data from medical charts of adult women who presented with HER2– ABC from February to May 2015 and from March to July 2017. Data were collected using a physician-reported form and a patient-reported form, which included questions on breast cancer history/treatment, and questions from PROs instruments (EuroQol 5-Dimensions 3-Levels [EQ-5D-3L], Brief Pain Inventory [BPI], European Organisation for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire Core 30 and its breast cancer module).Results: In total, 742 oncologists provided data for 6161 patients; 27.5% were tested for BRCA1/2mut. Out of the total patient population, 3.8% had BRCA1/2mut, 16.6% BRCA1/2 wild-type (BRCA1/2wt), and 79.5% were BRCA1/2 unknown (BRCA1/2unk). Hormone receptor-positive (HR+)/HER2- ABC was more frequent within the BRCA1/2wt versus BRCA1/2mut group, and triple-negative breast cancer (TNBC) within the BRCA1/2mut versus BRCA1/2wt group. More patients with HR+/HER2- ABC with BRCA1/2mut received chemotherapy (with or without targeted or endocrine therapy) versus BRCA1/2wt (66.0% vs 50.4%; p&lt;0.01); more patients had ≥1 AE (58.0% vs 39.1%; p&lt;0.001). Among patients with BRCA1/2mut versus BCRA1/2wt, a significantly higher proportion had some problems or worse in pain discomfort (p=0.021) and anxiety/depression (p=0.007) as measured by the EQ-5D-3L; role functioning (p&lt;0.01) and dyspnea (p&lt;0.05) measured by EORTC were worse with BRCA1/2mut. Pain scores by BPI were similar between groups.Conclusions: In patients with HER2- ABC in the real-world setting, more patients with BRCA1/2mut had TNBC, received chemotherapy, had &gt;1 AE, and experienced increased discomfort, anxiety, and dyspnea and diminished role functioning versus patients with BRCA1/2wt.

breast care

Treatment Patterns, Safety, and Patient Reported Outcomes among Adult Women with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer with or without, or with Unknown, &lt;b&gt;&lt;i&gt;BRCA1/2&lt;/i&gt;&lt;/b&gt; Mutation(s): Results of a Real-World Study from the United States, United Kingdom, and four EU Countries